2X-121

DB16063InvestigationalSmall molecule

2X-121 is under investigation in clinical trial NCT03562832 (Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP).

Mechanism: Pharmacologically active on Poly [ADP-ribose] polymerase 2 and Poly [ADP-ribose] polymerase 1
Curator reviewed
Formula / weight: C₁₈H₁₅N₅O · 317.352 g/mol (avg)
Also known as: Stenoparib
Code names: 2X-121 · E-7449

Resolves to

Compound

UNII9X5A2QIA7CCAS1140964-99-3ChEMBLCHEMBL3644587

Structure

InChIKeyJLFSBHQQXIAQEC-UHFFFAOYSA-NSMILESO=C1NN=C2NC(CN3CC4=C(C3)C=CC=C4)=NC3=C2C1=CC=C3

Targets

Q9UGN5PARP2P09874PARP1O95271TNKSQ9H2K2TNKS2

What you can answer from here — as of June 15, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

16+ReferencesStructured and connected to the statements they support

Which drugs share a target with 2X-121, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account